Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib. Academic Article uri icon

Overview

publication date

  • October 1, 2014

Research

keywords

  • Adenocarcinoma
  • ErbB Receptors
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Quinazolines

Identity

PubMed Central ID

  • PMC4655969

Scopus Document Identifier

  • 84925813420

Digital Object Identifier (DOI)

  • 10.1097/JTO.0000000000000221

PubMed ID

  • 25521405

Additional Document Info

volume

  • 9

issue

  • 10